E
CLDX icon

Ergoteles’s Celldex Therapeutics CLDX Stock Holding History

Ergoteles’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35,629
Closed -$1.28M – 1106
2023
Q1 		$1.28M Sell
35,629
-391
-1% -$16.9K 0.05% 406
2022
Q4 		$1.61M Buy
+36,020
New +$1.29M 0.06% 328
2022
Q2 		– Sell
-11,702
Closed -$399K – 1681
2022
Q1 		$399K Sell
11,702
-4,459
-28% -$143K 0.02% 750
2021
Q4 		$624K Buy
+16,161
New +$704K 0.02% 561
2021
Q1 		– Sell
-31,500
Closed -$552K – 827
2020
Q4 		$552K Buy
+31,500
New +$567K 0.02% 432

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Ergoteles's CLDX Position: Q2 2023 in Review

Ergoteles sold out of Celldex Therapeutics (CLDX) in Q2 2023, closing a stake of 35,629 shares — an estimated $1.28M sold.

Ergoteles first reported a position in CLDX in Q4 2020 and held it in 5 quarters. The position peaked at $1.61M in Q4 2022. 150 funds tracked by Wall St. Rank hold CLDX as of Q2 2023.

  • Ergoteles reported no remaining Celldex Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 35,629 Celldex Therapeutics shares in Q2 2023, an estimated $1.28M.
  • Ergoteles first reported a position in Celldex Therapeutics in Q4 2020 and held it in 5 quarters.
  • Ergoteles's Celldex Therapeutics position peaked at $1.61M in Q4 2022.
  • 150 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.